智通财经APP获悉，三生制药(01530)现涨超5%，截至发稿，涨5.13%，报23.36港元，成交额3.02亿港元。
消息面上，据中国国家药品审评中心（CDE）官网最新公示，沈阳三生制药有限责任公司申报的1类新药SSS68注射液（长效抗APRIL/BAFF双抗）临床试验申请获默示许可，拟开发适应症为：用于治疗原发性膜性肾病（pMN）、狼疮肾炎（LN）、免疫球蛋白A肾病（IgAN）。值得一提的是，SSS68注射液是全球首个进入临床阶段的APRIL×BAFF双抗。
值得注意的是，4月28日，三生制药自主研发的1类治疗用生物制品SSGJ-706注射液新药临床试验申请正式获得受理。SSGJ-706是三生制药完全自主研发的新一代肿瘤免疫治疗药物，注册分类为治疗用生物制品1类新药，是国内少数进入IND申报阶段的PD-1/IL-15双功能融合蛋白，核心创新在于解决了免疫细胞因子药物长期以来的临床应用痛点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.